[1]Cheang MC, Chia SK, Voduc D, et al.Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer[J].J Natl Cancer Inst, 2009, 101:736-750
[2]Jung S, Jeong J, Shin SH, et al.Accumulation of p53 determined by immunohistochemistry as a prognostic marker in node negative breast cancer; analysis according to St Gallen consensus and intrinsic subtypes. [J].J Surg Oncol, 2011, 103:207-211
[3] Kim HS, Yom CK, Kim HJ, et al.Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.[J].Breast Cancer Res Treat, 2010, 121:777-788
[4] Tang P, Wang J, Hicks DG, et al.A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. [J].Cancer Invest, 2010, 28:978-982
[5] Flanagan MB, Dabbs DJ, Brufsky AM, et al.Histopathologic variables predict Oncotype DX recurrence score.[J].Mod Pathol, 2008, 21:1255-1261
[6] Wolf I, Ben-Baruch N, Shapira-Frommer R, et al.Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study[J].Cancer, 2008, 112:731-736
[7]Langer!d A, Zhao H, Borgan ?, et al.TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.[J].Breast Cancer Res, 2007, 9(R30):- |